Incentivizing Drug Development in Serious Mental Illness


      Serious mental illness (SMI) imposes a significant burden on individuals and society. Individuals living with SMI have worse expected health, education, and career outcomes during their lifetime. Although treatments exist, pharmaceutical innovation in this area has lagged many other disease areas, despite an important need for new treatments. This report describes barriers that have hindered innovation and the development of new drugs for SMI, including science and research, regulatory, and health system barriers. To address these barriers, this report presents policies that may incentivize investment in this area.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Substance Abuse and Mental Health Services Administration. 2020 NSDUH Detailed Tables.

      2. National Institute of Mental Health. Mental Illness. Accessed July 22, 2021.

      3. Schizophrenia & Psychosis Action Alliance. Societal Costs of Schizophrenia and Related Disorders.

      4. National Institute of Mental Health. Bipolar Disorder. Accessed December 20, 2021.

      5. Reinert M, Nguyen T, Fritze D. 2021: The State of Mental Health in America. Mental Health America.

        • Ettman CK
        • Abdalla SM
        • Cohen GH
        • Sampson L
        • Vivier PM
        • Galea S.
        Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic.
        JAMA Netw Open. 2020; 3e2019686
        • McGinty EE
        • Presskreischer R
        • Han H
        • Barry CL.
        Psychological distress and loneliness reported by US adults in 2018 and April 2020.
        JAMA. 2020; 324: 93-94
        • Bahorik AL
        • Satre DD
        • Kline-Simon AH
        • Weisner CM
        • Campbell CI.
        Serious mental illness and medical comorbidities: findings from an integrated health care system.
        J Psychosomat Res. 2017; 100: 35-45
        • Mangurian CV
        • Schillinger D
        • Newcomer JW
        • et al.
        Diabetes and prediabetes prevalence by race and ethnicity among people with severe mental illness.
        Diabetes Care. 2018; 41: e119-e120
        • Seabury SA
        • Axeen S
        • Pauley G
        • et al.
        Measuring the lifetime costs of serious mental illness and the mitigating effects of educational attainment.
        Health Aff (Millwood). 2019; 38: 652-659
        • Tikkanen R
        • Fields K
        • Williams II, RD
        • Abrams MK
        Mental Health Conditions and Substance Use: Comparing U.S. Needs and Treatment Capacity With Those in Other High-Income Countries.
        Commonwealth Fund. 2020;
        • Holliday SB.
        The Relationship Between Mental Health Care Access and Suicide RAND Corporation.
        Updated. 2018;
      6. OECD Data. Suicide Rates.

      7. Substance Abuse and Mental Health Services Administration. Serious Mental Illness Among Adults Below the Poverty Line. Accessed December 2, 2021.

        • Anakwenze U
        • Zuberi D.
        Mental health and poverty in the inner city.
        Health Soc Work. 2013; 38: 147-157
        • Peterson J
        • Heinz K.
        Understanding offenders with serious mental illness in the criminal justice system.
        Mitchell Hamline Law Rev. 2016; 42: 538-563
      8. Substance Abuse and Mental Health Services Administration. Principles of Community-based Behavioral Health Services for Justice-involved Individuals: A Research-based Guide.

      9. National Alliance for Caregiving. On Pins & Needles: Caregivers of Adults with Mental Illness.

        • LavelleBowden TA
        • Wittenberg E
        • Lamarand K
        • Prosser LA
        Variation in the spillover effects of illness on parents, spouses, and children of the chronically ill.
        Appl Health Econ Health Policy. 2014; 12: 117-124
        • Silver N.
        What Are the Long-Term Effects of Bipolar Disorder on the Body?.
        Healthline. August 16, 2021; (Accessed)
        • Bowden CL
        • Perlis RH
        • Thase ME
        • et al.
        Aims and results of the NIMH systematic treatment enhancement program for bipolar disorder (STEP-BD).
        CNS Neurosci Ther. 2012; 18: 243-249
        • Rush AJ
        • Trivedi MH
        • Wisniewski SR
        • et al.
        Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
        Am J Psychiatry. 2006; 163: 1905-1917
      10. National Alliance on Mental Illness. Mood Disorder: Survey Report. 2021. Accessed July 29, 2022.

      11. National Institute of Mental Health. Major Depression. Accessed July 22, 2021.

      12. Treatment Advocacy Center. Bipolar Disorder - Fact Sheet. Accessed August 16, 2021.

      13. Treatment Advocacy Center. Schizophrenia - Fact Sheet. Accessed January 19, 2022.

        • O'Brien PL
        • Thomas CP
        • Hodgkin D
        • Levit KR
        • Mark TL.
        The diminished pipeline for medications to treat mental health and substance use disorders.
        Psychiatr Serv. 2014; 65: 1433-1438
        • Hyman SE.
        Revolution stalled.
        Sci Transl Med. 2012; 4: 155cm11
        • Gordon JA.
        From neurobiology to novel medications: a principled approach to translation.
        Am J Psychiatry. 2019; 176: 425-427
        • Hyman SE.
        Revitalizing psychiatric therapeutics.
        Neuropsychopharmacology. 2014; 39: 220-229
        • Howes OD
        • Mehta MA.
        Challenges in CNS drug development and the role of imaging.
        Psychopharmacology (Berl). 2021; 238: 1229-1230
        • Califf RM.
        Biomarker definitions and their applications.
        Exp Biol Med. 2018; 243: 213-221
        • García-Gutiérrez MS
        • Navarrete F
        • Sala F
        • Gasparyan A
        • Austrich-Olivares A
        • Manzanares J.
        Biomarkers in psychiatry: concept, definition, types and relevance to the clinical reality.
        Front Psychiatry. 2020; 11: 432
        • American Psychiatric Association
        Diagnostic and statistical manual of mental disorders.
        5th ed. 2013
        • Chen YF
        • Yang Y
        • Hung HMJ
        Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials.
        Contemp Clin Trials. 2011; 32: 592-604
        • Lietzan E
        • Acri née Lybecker KML
        The innovation paradox: pharmaceutical marketing exclusivity and incentives for drug development.
        J Pharm Health Serv Res. 2019; 10: 169-175
        • Gribkoff VK
        • Kaczmarek LK.
        The Need for new approaches in CNS drug discovery: why drugs have failed, and what can be done to improve outcomes.
        Neuropharmacology. 2017; 120: 11-19
        • Globe Newswire
        CNS Drugs Take 20% Longer to Develop and 38% Longer to Approve vs. Non-CNS Drugs, According to the Tufts Center for the Study of Drug Development.
        2022 (Accessed January 20)
        • Moses III, H
        • Matheson DHM
        • Cairns-Smith S
        • George BP
        • Palisch C
        • Dorsey ER
        The anatomy of medical research: US and international comparisons.
        JAMA. 2015; 313: 174-189
        • MacEwan JP
        • Seabury S
        • Aigbogun MS
        • et al.
        Pharmaceutical innovation in the treatment of schizophrenia and mental disorders compared with other diseases.
        Innov Clin Neurosci. 2016; 13: 17-25
        • National Institute of Health
        Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC).
        2021 (Updated June 25)
      14. National Institutes of Health. The BRAIN Initiative: Overview. Accessed August 21, 2021.

        • Ngai J.
        BRAIN 2.0: Transforming neuroscience.
        Cell. 2022; 185: 4-8
      15. Association of American Medical Colleges. President Signs FY 2022 Funding Bill with Increases for Research, Health Programs. Accessed Apr 19, 2022.

      16. National Institutes of Health. Proposed Advanced Research Projects Agency for Health (ARPA-H): Mission and Concept. Accessed November 30, 2021.

      17. McCallion J. 10 amazing DARPA inventions: how they were made and what happened to them. ITPro. Accessed Apr 19, 2022.

      18. National Institutes of Health. Accelerating Medicines Partnership (AMP). Accessed November 29, 2021.

        • National Institutes of Health
        Accelerating Medicines Partnership (AMP): Schizophrenia.
        Accessed. December 20, 2021;
      19. United States Code. Title 35 - PATENTS. Accessed August 23, 2021.

        • Choi DW
        • Armitage R
        • Brady LS
        • et al.
        Medicines for the mind: policy-based "pull" incentives for creating breakthrough CNS drugs.
        Neuron. 2014; 84: 554-563
        • Huskamp HA
        • Donohue JM
        • Koss C
        • Berndt ER
        • Frank RG.
        Generic entry, reformulations and promotion of SSRIs in the US.
        Pharmacoeconomics. 2008; 26: 603-616
        • Petersen M.
        Lilly Set Back in Patent Case over Prozac.
        New York Times. August 10 2000; (Accessed July 182022)
      20. Lilly holds onto Zyprexa patent.
        Nat Rev Drug Discov. 2005; 4: 450
      21. Office of Inspector General. The Orphan Drug Act: Implementation and Impact. Department of Health and Human Services.

        • Miller K
        • Fermaglich L
        • Maynard J.
        Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases.
        Orphanet J Rare Dis. 2021; 16: 1-10
        • Outterson K
        • Boucher HW
        • Engel A
        • Conti RM
        • Gracia G.
        Antimicrobial resistance: what’s at stake and what are we doing about it?.
        Health Affairs Forefront. March 4, 2022;
        • Eichler HG
        • Baird LG
        • Barker R
        • et al.
        From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients.
        Clin Pharmacol Ther. 2015; 97: 234-246
        • Avitzur O.
        Statement for the record on “The Path Forward: Advancing Treatments and Cures for Neurodegenerative Diseases.
        American Academy of Neurology. Updated. July 28, 2021;
      22. American Brain Coalition. Advocate for an FDA neuroscience center of excellence! Accessed August 26, 2021.

        • Blume-Kohout ME
        • Sood N.
        Market size and innovation: effects of Medicare Part D on pharmaceutical research and development.
        J Public Econ. 2013; 97: 327-336
        • Besanko D
        • Dranove D
        • Garthwaite C.
        Insurance access and demand response: pricing and welfare implications.
        J Health Econ. 2020; 73102329
        • Dixon LB
        • Holoshitz Y
        • Nossel I.
        Treatment engagement of individuals experiencing mental illness: review and update.
        World Psychiatry. 2016; 15: 13-20
        • Satiani A
        • Niedermier J
        • Satiani B
        • Svendsen DP.
        Projected workforce of psychiatrists in the United States: a population analysis.
        Psychiatr Serv. 2018; 69: 710-713
        • Mark TL
        • Parish W
        • Zarkin GA
        • Weber E.
        Comparison of Medicaid reimbursements for psychiatrists and primary care physicians.
        Psychiatr Serv. 2020; 71: 947-950
      23. Garthwaite C, Sachs R, Stern AD. Which markets (don't) drive pharmaceutical innovation? evidence from U.S. Medicaid expansions. National Bureau of Economic Research.

      24. Williams D. Mental health system overhaul clears Georgia Senate committee. Savannahnow. Accessed Apr 19, 2022.

      25. Creasy L. Loan repayment program helps keep licensed professionals in W. Va. The Herald-Dispatch. Accessed Apr 19, 2022.

        • Zerhouni EA.
        Translational Research: Moving Discovery to Practice.
        Clinical Pharmacology & Therapeutics. 2006;